SPECIFIC ANTIBODY TO S100A4 OR ITS FRAGMENT (VERSIONS), METHOD OF PRODUCTION THEREOF (VERSIONS), PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUNDS, HYBRIDOMA CELL LINE (VERSIONS), CONJUGATE, COMPOSITION, METHOD OF PREVENTING AND/OR TREATING CANCER, METASTASIS, ANGIOGENESIS AND INFLAMMATORY DISEASES, METHOD AND KIT FOR DIAGNOSING CANCER OR DISEASE ASSOCIATED WITH INFLAMMATION (VERSIONS), METHOD OF DETECTING S100A4, METHOD OF MAKING INDIVIDUAL THERAPY Russian patent published in 2017 - IPC C07K16/18 C07K16/46 A61K39/395 A61P35/00 A61K45/06 

FIELD: biochemistry.

SUBSTANCE: invention relates to biochemistry. Antibody to S100A4 characterized by antiangiogenic activity or its fragment in fact, preserving antiangiogenic activity of above antibody are described, wherein antibody is produced by hybridoma ECACC 10022401. Antibody contains at least area VL containing sequence SEQ ID NO: 1, and at least area VH containing sequence SEQ ID NO: 2, and identifies epitope containing sequence SEQ ID NO: 3, and it is characterized by activity profile, presented in Fig. 15. Antibody to S100A4 characterized by antiangiogenic activity or its fragment in fact preserving antiangiogenic activity of above antibody are also described, wherein antibody is produced by hybridoma selected from group comprising ECACC 11051801, ECACC 11051802 and ECACC 11051803, identifies epitope containing sequence SEQ ID NO: 24, and it is characterized by activity profile, presented in Fig. 15. Use of above antibodies in certain applications is also described.

EFFECT: invention extends range of products for preventing and/or treating cancer, metastasis, angiogenesis and inflammatory diseases.

36 cl, 26 dwg, 4 tbl, 16 ex